Total Payments
$7,119
2023 Payments
$180.00
Companies
5
Transactions
38
Medicare Patients
793
Medicare Billing
$105,028
Payment Breakdown by Category
Research$4,650 (65.3%)
Other$2,150 (30.2%)
Gifts$180.00 (2.5%)
Food & Beverage$128.78 (1.8%)
Education$10.40 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4,650 | 31 | 65.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,150 | 1 | 30.2% |
| Gift | $180.00 | 1 | 2.5% |
| Food and Beverage | $128.78 | 3 | 1.8% |
| Education | $10.40 | 2 | 0.1% |
Payments by Type
Research
$4,650
31 transactions
General
$2,469
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TESARO, Inc. | $4,660 | 33 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $2,150 | 1 | $0 (2017) |
| Intuitive Surgical, Inc. | $180.00 | 1 | $0 (2023) |
| HOLOGIC INC | $109.66 | 2 | $0 (2019) |
| Ethicon US, LLC | $19.12 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $180.00 | 1 | Intuitive Surgical, Inc. ($180.00) |
| 2019 | $865.99 | 7 | TESARO, Inc. ($750.00) |
| 2018 | $1,823 | 15 | TESARO, Inc. ($1,810) |
| 2017 | $4,250 | 15 | AstraZeneca Pharmaceuticals LP ($2,150) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/10/2023 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Gift | In-kind items and services | $180.00 | General |
| Category: SURGERY | ||||||
| 05/05/2019 | HOLOGIC INC | Tomosynthesis (Device) | Food and Beverage | In-kind items and services | $96.87 | General |
| Category: Breast and Skeletal Health | ||||||
| 04/01/2019 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 03/08/2019 | Ethicon US, LLC | Enseal X1 5mm (Device) | Food and Beverage | In-kind items and services | $19.12 | General |
| Category: Energy | ||||||
| 03/01/2019 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 02/01/2019 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 01/01/2019 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 01/01/2019 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 12/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 11/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 10/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 09/20/2018 | TESARO, Inc. | ZEJULA (Drug) | Education | In-kind items and services | $5.51 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2018 | TESARO, Inc. | ZEJULA (Drug) | Education | In-kind items and services | $4.89 | General |
| Category: ONCOLOGY | ||||||
| 09/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 08/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 07/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 06/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 05/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 04/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 03/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 02/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 01/27/2018 | Hologic, LLC | UNIVERSAL (Device) | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: Diagnostics | ||||||
| 01/01/2018 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 12/01/2017 | TESARO, Inc. | ZEJULA (Drug) | — | Cash or cash equivalent | $150.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY • Category: ONCOLOGY | ||||||
| 11/21/2017 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | TESARO, Inc. | $4,650 | 31 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 212 | 314 | $143,071 | $28,913 |
| 2022 | 7 | 221 | 315 | $151,795 | $30,308 |
| 2021 | 7 | 223 | 309 | $152,185 | $31,789 |
| 2020 | 5 | 137 | 204 | $80,710 | $14,018 |
Total Patients
793
Total Services
1,142
Medicare Billing
$105,028
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 80 | 131 | $49,125 | $10,081 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 50 | 85 | $46,750 | $9,948 | 21.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $18,105 | $3,373 | 18.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 19 | $14,155 | $3,040 | 21.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $13,958 | $2,068 | 14.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 36 | 48 | $978.00 | $403.20 | 41.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 72 | $39,600 | $8,451 | 21.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 69 | 104 | $39,000 | $8,003 | 20.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 32 | $23,840 | $5,054 | 21.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $23,430 | $4,744 | 20.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $19,940 | $2,977 | 14.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 17 | 20 | $5,085 | $945.72 | 18.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 33 | 45 | $900.00 | $133.26 | 14.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 43 | 79 | $43,450 | $9,523 | 21.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 31 | 45 | $33,525 | $7,699 | 23.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 54 | 77 | $28,875 | $6,352 | 22.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 28 | 28 | $29,820 | $5,446 | 18.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $11,670 | $1,799 | 15.4% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 16 | 17 | $3,825 | $817.05 | 21.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 39 | 51 | $1,020 | $153.00 | 15.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 47 | 83 | $45,650 | $7,513 | 16.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 39 | 50 | $18,750 | $3,507 | 18.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 13 | 13 | $11,050 | $2,085 | 18.9% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 15 | 20 | $4,500 | $799.15 | 17.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 23 | 38 | $760.00 | $113.34 | 14.9% |
About Dr. Eva Chalas, M.D
Dr. Eva Chalas, M.D is a Gynecologic Oncology healthcare provider based in Mineola, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1376542829.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eva Chalas, M.D has received a total of $7,119 in payments from pharmaceutical and medical device companies, with $180.00 received in 2023. These payments were reported across 38 transactions from 5 companies. The most common payment nature is "" ($4,650).
As a Medicare-enrolled provider, Chalas has provided services to 793 Medicare beneficiaries, totaling 1,142 services with total Medicare billing of $105,028. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Location Mineola, NY
- Active Since 07/18/2005
- Last Updated 03/03/2021
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1376542829
Products in Payments
- ZEJULA (Drug) $4,660
- LYNPARZA (Drug) $2,150
- Da Vinci Surgical System (Device) $180.00
- Tomosynthesis (Device) $96.87
- Enseal X1 5mm (Device) $19.12
- UNIVERSAL (Device) $12.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.